Inhibitors of these immune checkpoints have been shown to have antitumor activity and may improve treatment response in NSCLC with an overall unresponsive TIME if combined with anti-PD-(L)1 antibodies, other ICIs, or other treatment modalities [81,145,146,147,148,149,150,151]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.